UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
INSIGHTS & ANALYSIS

Clinical Trials

Clinical trials coverage from Pharma Journal: trial design, regulatory milestones, patient recruitment and phase readouts across the UK and global pipeline. The studies shaping tomorrow's medicines, from first-in-human work to pivotal results and the approvals that follow.

Clinical Trials11 November 2026· 8 min read

Foundayo gets CHMP backing for obesity and type 2 diabetes

The CHMP has issued a positive opinion on Foundayo (orforglipron) for obesity and type 2 diabetes. We examine the ATTAIN-1 data and regulatory next steps.

By Dr. Eleanor Vance, Regulatory Affairs Editor

Clinical Trials31 October 2026· 8 min read

Weltruza Olanzapine Injection Gets FDA Approval in Schizophrenia

In the SOLARIS trial, Weltruza lowered schizophrenia symptom scores by 9.75 to 11.27 points more than placebo at 8 weeks, with more weight gain and no peer-reviewed report yet. It is not approved in the UK or EU.

By Pharma Journal Editorial Desk, Editorial Desk

Clinical Trials20 October 2026· 9 min read

FDA Approves Atezolizumab for Stage III dMMR Colon Cancer

The FDA approved atezolizumab for stage III dMMR colon cancer on 8 October 2026. Here is what the ATOMIC trial numbers actually show — and what remains unknown.

By Dr. Eleanor Vance, Regulatory Affairs Editor

Clinical Trials5 October 2026· 7 min read

What the New UK Clinical Trials Regulations Mean for Sponsors

The UK's new clinical trials regulations enter force 28 April 2026. Here is what the notification scheme, combined review, and results disclosure obligations mean for sponsors and CROs.

By Dr. Eleanor Vance, Regulatory Affairs Editor

Clinical Trials10 September 2026· 7 min read

Semaglutide Trial Data in Early Alzheimer Disease Shows a Signal

The primary endpoint data from the EVOKE and EVOKE Plus trials, presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in late 2024 and subsequently reported in Nature Medicine (2025), show that semaglutide (Novo Nordisk; Ozempic at 1mg subcutaneous weekly)…

By Tom Okafor, Clinical Trials Correspondent

Clinical Trials20 August 2026· 6 min read

Personalised Cancer Vaccines Cross a Threshold: What the Melanoma Result Means for Oncology

A bespoke mRNA vaccine built from a patient’s own tumour, given with Keytruda, kept high-risk melanoma from returning in a phase 3 trial. The proof of principle now shifts the hard problem to manufacturing and regulation.

By Tom Okafor, Clinical Trials Correspondent

Clinical Trials14 July 2026· 8 min read

What the New UK Clinical Trials Regulations Mean for Sponsors

The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025, signed into law in April 2025 and entering into force on 28 April 2026, represent the most substantial revision to the UK clinical trial regulatory framework since the original 2004 Regulations…

By Dr. Eleanor Vance, Regulatory Affairs Editor

Clinical Trials6 July 2026· 9 min read

DTP3 Signals A New Route for Relapsed Myeloma Care

DTP3 multiple myeloma development targets a cancer-restricted NF-kB survival switch. Could this first-in-class peptide open a new lane for relapsed and refractory patients?

By Tom Okafor, Clinical Trials Correspondent

Clinical Trials29 June 2026· 11 min read

UK sets pathway for in vivo CRISPR gene editing trials

The UK is advancing in vivo CRISPR gene editing beyond ex vivo models. Explore regulatory signals, lipid nanoparticle delivery, and NHS reimbursement challenges.

By Dr. Eleanor Vance, Regulatory Affairs Editor

Clinical Trials17 June 2026· 10 min read

Microbiome on a chip could cut drug trial failures

Microbiome on chip systems could revolutionise drug discovery by providing human-relevant gut testing, potentially reducing the 90% clinical trial failure rate.

By Tom Okafor, Clinical Trials Correspondent

Clinical Trials10 June 2026· 14 min read

UK Clinical Trial Reforms 2026: Accelerating Approvals

The UK clinical trial regulation package, taking effect on 28 April 2026, is designed to deliver faster, more predictable approvals while preserving participant protections. Its headline operational c

By Tom Okafor, Clinical Trials Correspondent

Clinical Trials2 January 2026· 12 min read

AI speeds drug discovery as pharma takes risks in 2026

AI drug discovery shifts from promise to operational impact as pharma adopts risk-on posture amid tightening patent cliff timeline in 2026.

By Tom Okafor, Clinical Trials Correspondent

Stay ahead of the curve

Subscribe to our weekly pharmaceutical intelligence digest

Browse

Popular Categories in Pharma Journal

OncologyBiotechnologyPharmaceutical CompaniesClinical ResearchRegulatory, Quality & ComplianceMedical Devices, Diagnostics & EquipmentImmunology & Inflammation
Neuroscience & CNSInfectious Disease & VaccinesRare DiseasesAnimal & Veterinary HealthIndustry Media & AssociationsCell & Gene TherapyDermatology & Aesthetics
Genomics & Precision MedicineRespiratoryCardiovascular & MetabolicContract ManufacturingConsulting, Advisory & MedCommsHaematologyOphthalmology
Private Medical Clinics (London)Recruitment & TalentDigital Health & AIFertility & IVFLab, Reagents & Research ToolsMedical & Health InsuranceWomen's Health

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy